Search
for
Sort by
Research 31–60 of 140
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- Early prediction of alopecia areata using machine learning modeling of neuro stress immune signatures from multi datasets
- New therapies for alopecia areata
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
- Clinical Perspectives on Alopecia: From Hair Follicle Biology to Advanced Therapies
- TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
- Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews
- Pharmacotherapy of alopecia areata
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
- Meta-Analysis of Gene Expression Reveals the Core Transcriptomic Profile of Lesional Scalp in Alopecia Areata
- Scalp hair cortisol concentration in patients with alopecia areata and correlate its level with the disease variables
- Exploring Factors That Influence the Measurement of Patient-Reported Impacts of Alopecia Areata
- Patient Validation of Estimation of Health Utility Values in Alopecia Areata
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Ritlecitinib in severe alopecia areata: a profile of its use
- El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
- A Bibliometric Analysis of Alopecia Areata Literature over the Past 50 Years.
- Az alopecia areata kezelésében alkalmazott baricitinib hatásosságának és biztonságosságának retrospektív vizsgálata = Efficacy and safety of baricitinib treatment in alopecia areata:a retrospective analysis
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
- The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
- Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- Irish dermatologists’ experience with JAK inhibitors in alopecia areata
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway